¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º sZF6h=67D  
o J;$sj  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ -_eLf#3  
mUF,@>o  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) UFb )AnK  
x5*!Wx   
1. ICAM-1 PBkt~=j  
0F><P?5  
2. interleukin 12(IL-12) _~iw[*#u  
J!U}iD@occ  
3. tumor infiltrating lymphocyte pr UM-u8  
gQ1;],_  
4. TCR/CD3 complex \&gB)czEO  
3y8G?LL/[7  
5. hematopoietin receptor family j9+w#G]hV  
=^50FI|  
6. individual idiotype(IdI) .gOL1`b*  
B%+T2=& $7  
7. integrin :@A9](gI  
_D(rI#q  
8. colony-stimulatory factor (CSF) um>6z_"  
#d2.\X}A"3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© [!]2 djc  
+-CtjhoS  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? s 15 oN  
N `F~n%N  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ;&-k#PE]/H  
-"60d @.  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ0o*8#i/)!3  
! lc[  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ RMWHN:9  
=uYYsC\T  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) @>>~CZ` l  
DG ;_Vg  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ JB]q   
zz4N5["  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) $#pP Z  
T\j{Bi5 \J  
3. immunoglobulin superfamily (IgSF) !SdS E^lz`  
% *INT  
4. selectin QD*35Y!d  
=Bhe'.]QSx  
5. anti-idiotypic antibody (¦ÁId) kN4{13Qs*  
(VEpVn3{  
6. major histocompatibility complex(MHC) A5R<p+t6  
l@+7:n4K0  
7. immunotolerance Q&=w_Wc  
,UGRrS  
8. biological reponse modifier(BRM) %Iv,@}kvT+  
"wn zo,  
9. immune reponse gene (Ir gene) ^!ZC?h!rG  
%9N7Ln|%  
10. reshaped antibody (or reconstituted antibody) ^2on.N q>  
iwp{%FF  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© }v!$dr,j '  
vV6I0  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 33ef/MElD$  
p~^D\jR.  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? wq(7|!Eix  
]?+p5;{y4  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Yu[ t\/  
>eqxV|]i  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? F6OpN "UM'  
Nj xoTLI  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ &U raUl  
YY )s p%  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 1#*a:F&re  
*`\ Pr  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ O[s{ Gk'>  
+ SFVv_n  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ f3&[#%  
D 38$`j  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? qY<'<T4\  
LuSLkLN  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡  fA<[f  
2FF4W54I  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: <2|O:G  
;04Ldb1{|3  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 8V)^R(\;  
pUq1|)g  
ÃâÒßѧ 4.h=&jz&  
Q/I! }C4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© IOoz^/'  
jJY"{foWV  
1. CD8 mc_ch$r!  
r77PQQD T  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Ikiib WQL+  
\2}bi:e 6  
3. immunoglobulin fold(Ig fold) <]4i`6{v  
1_ C]*p  
4. cadherin (Ca-dependent cell adhesion moleculers) Bj}^\Pc;}  
&A)B~"[~  
5. idiotype-anti-idiotypic antibody immune network theory x.zbD8l/9  
)\be2^p  
6. HLA class II antigen 0iK;Egwm  
UIAj]   
7. complementarity-determining region (CDR) .YnFH$;$  
0=q;@OIf  
8. perforin(or pore-forming protein ,PFP) RE=+ Dz{  
E%v?t1>/  
9. high affinity IL-2 receptor 4e;y G>  
f<*Js)k  
10. artificial active immunization s^|.Zr;,>  
nF4a-H&Fo  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© +sx 8t  
L%$|^T=%  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠUH>F|3"d  
u4neXYSy  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Ppt2A6W  
~+ bGN  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ G0{H5_h  
f\1A! Yp  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 8kt5KnD2  
G,<T/f .{$  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ Gqcz< =/  
fr}Eaa-{^  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? k@D0 {z  
uV hCxUMQ  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Rqy0Q8K<  
IU]^&e9u  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ P;8>5;U4-  
^*= 85iyo  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ,prF6*g+WE  
\[>9UC%  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ XJ+6FT/qss  
 \^K&vW;  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© &G>(9  
n*'<uKpM  
1. immunoglobulin gene rearrangement " ;w}3+R  
gbStAr.  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) M4L ktR-[  
,kp\(X[J  
3. flow cytometry(FCM) 9>#:/g/  
` C+HE$B  
4. carrier effect uH^ PQ  
5;TuVU.8Q  
5. positive selection of T lymphocytes in thymus b~C$R[S  
5NXt$k5  
6. mouse TH1(Th1) and TH2(Th2) subsets F{\gc|!i  
rn:!dV[  
7. perforin (pore-forming protein ,PFP) 6`"M  
])#\_ ' fg  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) `wTlyS3[  
[$(R#tZ+  
9. SH-2(src-homology region 2) MY nH2w]  
]y)Q!J )Q  
10. Ab2¦Â (internal image) c| ' w  
f|aDTWF  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© j%*7feSNC  
E)t  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? "] -],K  
&,-p',\-  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? _# qe #  
?Zyok]s  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ^2M!*p&h  
jlKGXD)Q[  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ EH+~].PJd  
MdhT!?  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ i j&p4  
/'>;JF  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) G\Q9IcJ0dY  
O rk  
ÃâÒßѧרҵ£º %f[Ep 3D  
%N~C vN@T  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ udTxNl!  
B$`lY DqaG  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? -%uy63LbHF  
VvgN3e[  
´«È¾²¡Ñ§×¨Òµ£º ^[M~K5Y  
5(}H ?  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ }g,X5v?W  
iAz UaF  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ &9k i O  
h1%y:[_  
Ïû»¯×¨Òµ£º \!X?zR_  
L/k40cEI^z  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ L+Nsi~YVq  
\3 KfD'L  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? F|]rA*2u  
G(i\'#5+  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ '{D%\w5{  
iy 3DX|]  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© !\w\ ]7 ls  
dt.- C_MO  
1. Fas(CD95)/FasL >DmRP7v   
cJq<9(  
2. common chain of cytokine receptor 7dhn'TW  
xhD$e= g  
3 . TCR/CD3 complex `hF;$  
?hSha)1:  
4. negaive selection of thymocytes uk{J@&F  
xfU hSt  
5. artificial active immune 6Wu*.53  
'h:!m/1  
6. anti-idiotypic { ;' :h  
`QAh5r"  
7. IgSF A@ { !:_55  
{G]`1Q1DR  
8. Integrin S%P3ek>3  
kBUufV~  
9. chemokine _PdAN= C3  
<e^6.!;W  
10. B7/CD28 |<2JQ[]  
5lG|A6+w{  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© {9,R@>R  
_.hIv8V  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ >T$7{ ~  
A<1l^%i  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 0I6499FQ  
KXDz'9_  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ dnLo(<{<U  
^w ]1qjGw  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Ld'EABM  
/G[+E&vj  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 1_XO3P\  
-y9Pn>~V  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ fa/P%9db  
re2Fv:4{  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© qL u8!|QT  
WCWSLEAza  
1. B7/CD28 6qY\7R2+  
`8qT['`#R  
2. Th1 subset f45;fT>   
O>kXysMv>  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© R'jUS7]Y  
A;b=E[i v  
4. antibody affinity maturation ?T$*5 d  
5n-9#J$  
5. AP-1 & T5f H!?4  
&*LA_]1@  
6. single chain variable fragment£¨ScFv£© wi![0IE )  
&zaW"uy3T  
7. NK cell receptor ~pDRF(  
!- Cs?  
8. Zinkernagel-Doherty phenomenon } D&"z8mP  
FCUVP,"T  
9. Ig fold }L{_xyi>#  
jb#1&L 14  
10. CD40/CD40L U4 go8  
~5XL@jI^  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© z&6]vN'  
YL0WUD_>  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 1"~O"msb  
P@o,4\;K  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ >b/k|?xP  
lN*1zM<6;  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ DkF@XK0c3  
GA%"w=M\  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ k*zc5ev}  
5 O{Ip-  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 3.GdKP.%  
gz)wUQ|W  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ cN[ q)ts  
x3p;H02i\  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ :"y7Weh  
+lk\oj$S+  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© |P[D2R}  
o q'J*6r  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©  5K_N  
Fh3Dc 83~  
1.Co-stimulators (or co-stimulating molecules) (dGM;Dq8  
G74a9li@  
2.NK-kB `*2*xDuP  
$ uIwRG <  
3.Immunoglobulin superfamily Pvb+   
(Db*.kd8,  
4.antigen-presenting cell (APC) HnKF# <  
ck4T#g;=  
5.death domain IZ(CRKCGBl  
vY+_tpuEH  
6.CCR and CXCR v#YS`];B  
s+\qie  
7.Lectin (or mitogen) l7r N  
;^H+ |&$>  
8.Clusters of differentiation, CD) =QxE-)v  
 kAe-d  
9.B7 family 9 %.<V_$  
q.hc%s2?  
10.Cytotoxic T lymphocyte, CTL) Hh'14n&W  
dxhjPS~^Q  
11.IL-15 and IL-15 receptor (IL-15R) A1s=;qr  
owS@dbO  
12.MHC restriction 1 0Tg > H  
P Tc\I  
13.Affinity-chromatography =D"63fP1  
CR|&VxA  
14.Cyctosprin A, CsA Jgj L$n;F  
r1H['{$  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) y2ws* IZ"  
u B%^2{uU  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© CCvBE, u x  
Y`_X@Q  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 {O,M}0Eg  
qYiK bzy  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 7(+ZfY~w"  
t>|N4o  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ WHj4#v (  
3 BhA.o  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 9 8BBsjkd  
i}{Q\#=#  
ÃâÒßѧרҵ£º $m0x8<7nu  
7D_kkhN  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ d"`>&8*  
&)}:Y!qiu  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 8q[WfD  
Cspm\F  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ ITY!=>S-  
?-&D'  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) YhK/pt43C  
]~ eWr2uG?  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) wgP3&4cSUc  
H D ^~4\%  
1. ADCC(antibody dependent cell-mediated cytotoxicity) U$J_:~  
x9 L \"  
2. »·æß¾úËØ(cyclosporin) g;Q^_4@  
l'8TA~  
3. KIR(killer cell inhibitory receptor) 2j BE+k"M  
BcO2* 3  
4. HLDA(human leucocyte differentiation antigen) o5@P>\ u>  
_ShJ3\,K  
5. Interleukin 18(IL-18) #IA(*oM  
R*#Q=_  
6. ÕûºÏËØ(integrin) 8=AKOOU7>  
<?}g[]i  
7. Fas/FasL UimZ/\r  
}H^^v[4  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) B y8Tw;aL  
F=c_PQO  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) R6.#gb8^oS  
Ci:Q Isu*  
10. Th1/Th2 `W S  
'F~SNIay  
11. »ùÒòÒßÃç(DNAÒßÃç) f#MN-1[67  
$^ 3 f}IzA  
12. chemokines and chemokine receptor m,q<R1  
Y)RikF >  
13. ÃâÒßÄÍÊÜ ;S j* {  
mmK_xu~f28  
14. ¹²´Ì¼¤·Ö×Ó !A0bbJ  
9?6$ 2I  
15. ËÀÍö½á¹¹Óò(death domain) :M`BVZ1t  
:UciFIa  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) j(2T,WM  
g"f^YEQ_  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? !IU*Ayg  
x{5*%}lX8  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠN`MQHQ1  
n\Nl2u& m  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 9$i`B>C~  
?F v(4g  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ h^,a 1'  
@I:&ozy }=  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå sJ=B:3jS0  
wl9icrR>  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ y0]O 6.{  
6 H.Da]hk  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 1uMdgrJRR  
} d6^  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ eH6cBX#P.  
dZ Z/(oE>  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ )-gyDA  
2t<CAKBB  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»